Cambridge Healthtech Institute’s Third Annual

Digital Pathology

Transforming Medicine in a Digital World

February 16-18, 2015 | Moscone North Convention Center | San Francisco, CA
Part of the 22nd Annual Molecular Medicine Tri-Conference


The field of pathology is being reshaped by advances in digital imaging techniques, systems for analyzing data and the increased demand for access. This conference will look at the present and future of digital pathology from many different aspects, including market projections and trends, to technical progress in imaging techniques, and approaches to mining and storage of big data. For digital imaging and molecular technologies to be utilized in routine practice, many factors influencing adoption should be evaluated, including regulation, standards, and validation of imaging methods. Learn how digital pathology is creating advanced diagnoses for the future.

Scientific Advisory Board

Kenneth J. Bloom, M.D., Chief Medical Officer, Clarient, Inc.

Eric F. Glassy, M.D., FCAP, Medical Director, Affiliated Pathologists Medical Group

Liron Pantanowitz, M.D., Associate Professor, Pathology, University of Pittsburgh Medical Center

David L. Rimm, M.D., Ph.D., Professor, Pathology, Yale University

Day 1 | Day 2 | Day 3 | Plenary Session | Download Brochure 




Monday, February 16

10:30 am Conference Program Registration


11:50 Chairperson’s Opening Remarks

Sharon Moulis, Ph.D., Director, Tissue Diagnostics Alliances, Definiens

12:05 pm Mobile Industry: Exploiting Smartphones for Digital Pathology

Douglas J. Hartman, M.D., Assistant Professor, Pathology, University of Pittsburgh Medical Center

Smartphones are rapidly being expanded with new and greater functionalities. The emerging field of mobile health (mHealth) has led to changes in all areas of healthcare. Many of these functionalities are directed to consumers, however, some can be exploited within pathology. Applications of smartphones for digital pathology (such as QA, educational, tumor boards, etc) and emerging image analysis capabilities will be discussed.

12:35 DIGITAL PATHOLOGY – Where We Have Been and the Future

Kim Dickinson, M.D., MBA, MPH, Medical Director, Lab Corp Clinical Trials; President, Digital Pathology Association

Digital pathology is a vital and important component in the future delivery of health care and will become increasingly more integral to pathologists and the patient’s care team. The discussion will provide a historical perspective of digital pathology, followed by a discussion of the future of digital pathology. The talk will also cover the current regulatory environment for digital imaging.

1:05 Session Break

1:15 Luncheon Presentation: How to Develop Fit-for-Purpose IHC Assays to Enable Clinical Trial Patient Stratification

Sharon Moulis, Ph.D., Director, Tissue Diagnostics Alliances, Definiens

This presentation will discuss how to devise a method of IHC assay design that increases the chance of finding the optimal cutpoint of biomarker expression and maximizing the chance of success for companion diagnostic use. Through use of standard curves and quantitative image analysis, the required target expression level can be determined and IHC assays re-optimized for more uniform and consistent scoring by a pathologist.

1:45 Session Break



2:30 Chairperson’s Remarks

Eric F. Glassy, M.D., FCAP, Medical Director, Affiliated Pathologists Medical Group

2:40 Gastrointestinal in vivo Microscopy: One Step Closer to Achieving the Fantastic Voyage

Gregory Y. Lauwers, M.D., Professor & Vice Chair, Pathology, Massachusetts General Hospital

Advances in in vivo microscopy technologies provide a unique opportunity for the pathologist and the gastroenterologist to evaluate large segments of the gastrointestinal tract in vivo. Although multiple challenges remain, it is certain that this technology will impact the clinical care of patients with gastrointestinal pathologies. Cooperation between clinicians, pathologists, and engineers will be cardinal in realizing this fantastic voyage.

3:10 No More Glass: Optical Coherence Tomography (OCT) Permits Pathologist-Ready Photomicrographs without Microscope Slides

Jeffrey Fine, M.D., Assistant Professor, Pathology, University of Pittsburgh School of Medicine

Optical Coherence Tomography (OCT) is an advanced imaging technique that permits rapid non-destructive microscopic tissue imaging. We will provide a pathologist-friendly overview of OCT, followed by a summary of our early ex-vivo imaging of breast and endometrial specimens. This work aims toward clinical application and toward OCT expertise that can support future in vivo applications. We will end with discussion of future trends for this technology.

3:40 26 Easy Steps to Implementing an in vivo Microscopy Service in Pathology

Andrew Quinn, M.D., Fellow, Cytology, Pathology, Brigham and Women’s Hospital

This talk will address one institution’s experiences implementing a clinical in vivo microscopy (IVM) service with particular attention paid to informatics and workflow considerations as well as potential pitfalls. It will additionally emphasize the rapidly evolving nature of the field and the growing need for participation by pathologists in all practice settings in this undertaking.

4:10 Collaboration Across Multi Disciplinary Teams 

Chrystal Adams, Associate Vice President, Marketing, XIFIN

Data show that when physicians across multiple disciplines (pathology, radiology, and oncology) collaborate, diagnoses are changed as much as 25% of the time. XIFIN’s collaborative medicine portal enables communication across physician specialties in a secure cloud environment.

4:40 Break and Transition to Plenary Session

5:00 Plenary Session Panel 

6:00 Grand Opening Reception in the Exhibit Hall with Poster Viewing

7:30 Close of Day

Day 1 | Day 2 | Day 3 | Plenary Session | Download Brochure 

Tuesday, February 17

7:00 am Registration and Morning Coffee

8:00 Plenary Session Panel 

9:00 Refreshment Break in the Exhibit Hall with Poster Viewing 


10:05 Chairperson’s Remarks

Liron Pantanowitz, M.D., University of Pittsburgh Medical Center

10:15 Large Scale Deployment of Digital Pathology: The Importance of Color

Elizabeth A. Krupinski, Ph.D., Professor, Medical Imaging, University of Arizona

Digital Pathology is growing – slowly. Although it is clearly feasible and likely has numerous benefits, there are some challenges that have limited large-scale deployment. One of those is color – from acquisition through display. This talk will discuss some of the challenges with color rendering with WSI as well as the potential impact on the pathologists and the interpretation task.

10:45 How Digital Pathology Enables New Business and Clinical Models in Pathology

Robert Michel, Editor-In-Chief, The Dark Report

Swift improvements to digital pathology technologies and systems—in tandem with healthcare’s evolution toward integrated clinical care—are creating opportunities for nimble anatomic pathology laboratories to deliver value in new ways. This presentation will identify how early-adopter pathologists are utilizing digital pathology to improve patient outcomes and describe some of the emerging pathology business models that utilize digital pathology.

11:15 Digital Pathology Patent Landscape: Insights into Emerging Trends and Opportunities

Sury Vepa, Ph.D., J.D., Senior Licensing and Patenting Manager, Office of Intramural Research; Office of Technology Transfer, NIH

Digital pathology has been increasingly used for education, clinical practice and research, and according to a recent market report, the global digital pathology market is expected to reach an estimated $437 million by 2018. The rapid development of digital pathology is made possible by innovations across a variety of specialties such as information management systems and imaging and visualization technologies, and a majority of these innovations are patented. This presentation will highlight emerging trends in digital pathology technologies based on a systematic review of the patenting activity and will use these trends to discuss potential new opportunities.

11:45 Digital Pathology: Regulatory Barriers to Adoption

Eric F. Glassy, M.D., FCAP, Medical Director, Affiliated Pathologists Medical Group

Widespread adoption of Digital Pathology is hampered by an uncertain regulatory landscape. This talk will canvass the key legal issues associated with integrating telepathology and whole slide imaging into a pathology practice.

12:15 pm Session Break

12:25 Luncheon Presentation: Bio-Formats & OMERO: Open Source, Enterprise Solutions for Managing, Sharing, Analysing, and Integrating Digital Pathology Data

Jason Swedlow, Ph.D., President & CEO, Glencoe Software Inc.

Glencoe Software's OMERO Data Management Engine is an enterprise-proven software platform that integrates digital pathology image data, metadata, analytics and annotations into a single system. OMERO enables data integration, large-scale analysis, and private or public data sharing. Based on a proven open source foundation, OMERO reads all major WSI formats with no data duplication and is the ideal system for delivering knowledge, discovery and diagnoses from image-based data.

12:55 Session Break

1:25 Refreshment Break in the Exhibit Hall with Poster Viewing


2:00 Chairperson’s Remarks

David L. Rimm, M.D., Ph.D., Yale University School of Medicine

2:10 Next-Generation Immunohistochemistry Using Multiplexed Ion Beam Imaging

Michael Angelo, M.D., Ph.D., Instructor, Pathology, Stanford University

Multiplexed ion beam imaging (MIBI) is a new method for simultaneously analyzing dozens of antigens in a single tissue section using primary antibodies that are labeled with mass reporters. This talk will review the working principles of MIBI and present potential applications in clinical diagnostics and basic research.

2:40 Multiplexed Immunofluorescence in Translational Research and Clinical Applications

Michael D. Feldman, M.D., Ph.D., Associate Professor, Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania

In this presentation, we will review the use of multiplexed immunofluorescence staining and imaging methods to extract cellular level information from FFPE samples. In specific clinical trial examples as well as applications to clinical use cases will be discussed.

3:10 Domain Specific Antibodies as Biomarkers

David L. Rimm, M.D., Ph.D., Professor, Pathology, Yale University School of Medicine

Biological processing of transmembrane ligands and receptors can provide information on tumor behavior. Differential outcome as a function of measurement of extracellular vs. the cytoplasmic domain of HER2 is shown as an example.

Leica Biosystems3:40 Reproducibility in Digital Pathology – The Last Step or the First in Standardization

Pawan Singh, Director, Workflow Solutions, Executive Management, Leica Biosystems

Increasing usage of digital pathology is promoting greater sharing of slides between organisations, often highlighting the different staining patterns and preferences between laboratories. Is this inherent variability in slide preparation something we should adjust for with digital pathology, or eliminate before slide scanning? We will look at a study measuring haematoxylin and eosin variation in serial sections and the challenges and benefits of utilising digital pathology, despite this variability.

4:10 Mardi Gras Celebration in the Exhibit Hall with Poster Viewing

5:00 Breakout Discussions in the Exhibit Hall

This interactive session provides attendees an opportunity to choose a specific discussion group to join. Each group has a moderator to ensure focused discussions around key issues within the topic. This format allows participants to meet potential collaborators, share examples from their work, vet ideas with peers, and be part of a group problem-solving endeavor. The discussions provide an informal exchange of ideas and are not meant to be a corporate or specific product discussion.

Informatics Role in the Changing Healthcare Environment

Douglas J. Hartman, M.D., Assistant Professor, Pathology, University of Pittsburgh Medical Center

  • Diagnostic reporting within an electronic environment
  • How pathology can augment decision support systems/analytics
  • Navigating various models for electronic health software platforms

Substantiating the Value of Whole Slide Imaging

Michael C. Montalto, Ph.D., Senior Vice President, Clinical, Medical & Scientific Affairs, GE Healthcare

  • How is the use of whole slide imaging being contemplated now or in the future in your institution?
  • How have you or how will you substantiate this value to your institution?
  • Are critical proof points required to demonstrate value during the purchasing process and, if so, what are they?
  • Are regulatory barriers seen as a main consideration for implementation? How does regulatory considerations compare to value and cost issues associated with WSI?
  • Are other members of the care pathway teams, including oncologists and patients, aware of the value that whole slide imaging may bring to the over-all improvement of care?

Digital Pathology Interoperability

Michael W. Riben, M.D., Medical Director, Laboratory Informatics; Associate Professor, Pathology, MD Anderson Cancer Center

  • Standards for Digital Imaging – does Dicom work? What should we do?
  • How do we exchange a case, not just an image?
  • What are the minimum requirements for Pathology PACS-LIS to PACS-LIS interoperability
  • How do we get the vendors on board – what is the rallying cry?
  • Is Digital Pathology Interoperability a Fed-ex killer?

6:00 Close of Day

Day 1 | Day 2 | Day 3 | Plenary Session | Download Brochure 



Wednesday, February 18

7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

8:00 Plenary Session Panel 

9:45 Refreshment Break and Poster Competition Winner Announced in the Exhibit Hall


10:35 Chairperson’s Remarks

Yukako Yagi, Ph.D., Massachusetts General Hospital & Harvard Medical School

10:45 Remote Eye Tracking to Assess Pathologist Interaction with Digital Whole Slide Images

Beverly E. Faulkner-Jones, M.D., Ph.D., Staff Pathologist, Pathology, Beth Israel Deaconess Medical Center

Digital whole slide images (WSIs) are increasingly being used in pathology for teaching and diagnosis. Although it is important to understand the visual process by which pathologists arrive at image-based diagnoses, little is known about this form of visual expertise. Using remote eye-tracking visualization of gaze patterns we are evaluating the way pathologists interact with WSIs to optimize presentation of digital image data.

11:15 High Resolution Histology 3D Reconstruction and Analysis

Yukako Yagi, Ph.D., Director, MGH Pathology Imaging & Communication Technology (PICT) Center, Massachusetts General Hospital; Affiliated Faculty, Wellman Center for Photomedicine, Massachusetts General Hospital; Assistant Professor of Pathology, Harvard Medical School

The quality of whole slide image based 3D model has been improving on the microscopic level (40x) and proving that there is strong value in pathology education and research. The protocols to build a high quality 3D reconstruction model and the volume based image analysis have been established. Some of the results on several research projects will be demonstrated.

11:45 Google Glass for Pathology

Liron Pantanowitz, M.D., Associate Professor, Pathology, University of Pittsburgh Medical Center

Google Glass is a head-mounted, wearable computer that can connect to the Internet and display information in a smartphone-like, hands-free format. Glass has great potential in healthcare. Recent studies have demonstrated utility for this novel device in Pathology, such as for telepathology. This talk will address the opportunities and challenges with using Google Glass in Pathology.

12:15 pm Enjoy Lunch on Your Own

1:00 Refreshment Break in the Exhibit Hall and Last Chance for Poster Viewing


1:40 Chairperson’s Remarks

Metin N. Gurcan, Ph.D., Associate Professor, Biomedical Informatics, The Ohio State University

1:50 Whole Slide Imaging Data Storage: A “Dickens” of a Tale -- “Please Sir, Can I Have Another Petabyte?”

Michael W. Riben, M.D., Medical Director, Laboratory Informatics; Associate Professor, Pathology, MD Anderson Cancer Center

As the penetration of whole slide imaging devices in pathology continues to expand, the challenge of managing, optimizing, and securing the imaging data and its storage becomes a high priority for successful integration into pathology clinical and research workflows. This presentation will highlight these challenges, look at potential strategies employed, and provide a framework for evaluating what is the best approach for your use cases.


2:20 Hot Spot Detection for Histopathological Images

Metin N. Gurcan, Ph.D., Associate Professor, Biomedical Informatics, The Ohio State University

Hotspot detection plays a key role in the diagnosis of several diseases including breast cancer and neuroendocrine tumors of the digestive system. In the Clinical Image Analysis Laboratory at the Ohio State University, we have been developing computerized image analysis algorithms for the detection of hot spots from Ki-67 stained slides. These methods rely on visually meaningful segmentation of images and novel clustering techniques.

2:50 Reimagining Cancer: The Opportunities and Challenges of Biomarker-Driven, Targeted Therapy

Mark Boguski, M.D., Ph.D., Founder & CMO, Genome Health Solutions

Biomarkers for precision medicine hold great promise for improving the outcomes of patients with cancer and other diseases. However there is a huge education gap among healthcare professionals in regional and community settings where >80% of cancer care is delivered. Traditional routes for the diffusion of knowledge and innovation are proving to be inadequate to close this gap. Furthermore the value propositions supporting the adoption of biomarker-driven, precision medicine are very unclear among healthcare executives and payers. These obstacles can be overcome by new platforms for molecular education and clinical decision support, but only if properly designed and deployed for the audiences that need them most.

3:20 Microscopy with UV Surface Excitation (MUSE): Towards Slide-Free Pathology

Richard Levenson, M.D., Professor and Vice Chair for Strategic Technologies, Pathology & Laboratory Medicine, UC Davis Medical Center

A new, inexpensive microscopy technique that allows for diagnostic-quality images to be obtained from tissues without fixation, freezing, paraffin-embedding or sectioning will be presented. In addition to recapitulating conventional histology, it can also reveal topographical features. MUSE should be useful for typical diagnostic applications, preclinical/basic research tissue characterization, and in global health settings.

3:50 Refreshment Break


4:00 Chairperson’s Remarks

Kenneth J. Bloom, M.D., GE Healthcare

4:10 Using Digital Imaging to Select Tumor Cells for NGS

Kenneth J. Bloom, M.D., Chief Medical Officer, Laboratory and Genomic Services, GE Healthcare

NGS holds the promise to allow precision medicine to become a reality in oncology management. Tumor heterogeneity is a major impediment that must be understood and overcome before this is possible. The use of digital imaging will allow the pathologist to select the most appropriate cells for analysis, to better understand the composition of the nucleic acids in the sample analyzed and to more precisely interpret the sequencing data.

4:40 Data Intensive Modeling of Biomedical Processes in Computational Pathology

Jonas S. Almeida, Ph.D., Professor and Division Director, Pathology, University of Alabama Birmingham

Fast growing public biomolecular Big Data resources provide a comprehensive context to the comparatively small data produced by individual experiments, or describing individual patients. The patient-derived cancer genomics data resources of the TCGA and ICGC initiatives are a prime example. This new data intensive Computational Pathology landscape includes both a new emphasis on real-time Machine Learning and on physician/patient-facing software development for personalized medicine.

5:10 Clinical Performance and Regulatory Considerations for in vitro Diagnostic Use of Whole Slide Imaging in the U.S.

Michael C. Montalto, Ph.D., Senior Vice President, Clinical, Medical & Scientific Affairs, GE Healthcare

This presentation will give a high level overview of the regulatory frame work for in vitro diagnostic devices in the United States specifically as it relates to whole slide imaging (WSI) technology, including the FDA’s current thoughts regarding WSI device classifications. Additionally, considerations for validating device performance for both manufactures and laboratories will be discussed.

5:40 Close of Conference Program

Day 1 | Day 2 | Day 3 | Plenary Session | Download Brochure 

Premier Sponsors:   


Jackson Laboratory - small logo  


 Precision for Medicine 


Silicon Biosystems 

Thomson Reuters-Large